- Synthesis and turnover of carnitine are regulated mainly by the kidney. Kidney carnitine levels inversely correlate with serum creatinine of normal subjects and CKD patients.
- Dialysis patients often develop carnitine deficiency. In hemodialysis, carnitine is cleared by 75% from the plasma during a 4-hour hemodialysis session leading to a 50% reduction after one year of hemodialysis of plasma and muscle carnitine.
- Carnitine deficiency may contribute to a number of clinical disorders such as EPO resistant anemia, cardiac dysfunction, cachexia, dyslipidemia, glucose intolerance and insulin resistance, muscle weakness, intradialytic hypotension and muscle cramps.
- Carnitine supplementation improves hemodynamic stability during hemodialysis session in adult patients, thereby avoiding repeated interruptions of the session resulting in a better control of related disorders.
- The administration of carnitine for kidney disease can improve metabolic balance and dialysis related disorders.
- This section includes monographs that comprehensively report the evidence that we have to date on
- L-carnitine and in its role in kidney disease. It also provides an overview of the current utilization of L-carnitine in kidney disease and dialysis.
- The section also includes educational videos, presentations and animated infographics edited by international scientific experts.
L-CARNITINE DEFICIENCY IN KIDNEY DISEASE AND DIALYSIS